353 related articles for article (PubMed ID: 35120664)
1. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Nguyen B; Fong C; Luthra A; Smith SA; DiNatale RG; Nandakumar S; Walch H; Chatila WK; Madupuri R; Kundra R; Bielski CM; Mastrogiacomo B; Donoghue MTA; Boire A; Chandarlapaty S; Ganesh K; Harding JJ; Iacobuzio-Donahue CA; Razavi P; Reznik E; Rudin CM; Zamarin D; Abida W; Abou-Alfa GK; Aghajanian C; Cercek A; Chi P; Feldman D; Ho AL; Iyer G; Janjigian YY; Morris M; Motzer RJ; O'Reilly EM; Postow MA; Raj NP; Riely GJ; Robson ME; Rosenberg JE; Safonov A; Shoushtari AN; Tap W; Teo MY; Varghese AM; Voss M; Yaeger R; Zauderer MG; Abu-Rustum N; Garcia-Aguilar J; Bochner B; Hakimi A; Jarnagin WR; Jones DR; Molena D; Morris L; Rios-Doria E; Russo P; Singer S; Strong VE; Chakravarty D; Ellenson LH; Gopalan A; Reis-Filho JS; Weigelt B; Ladanyi M; Gonen M; Shah SP; Massague J; Gao J; Zehir A; Berger MF; Solit DB; Bakhoum SF; Sanchez-Vega F; Schultz N
Cell; 2022 Feb; 185(3):563-575.e11. PubMed ID: 35120664
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Zehir A; Benayed R; Shah RH; Syed A; Middha S; Kim HR; Srinivasan P; Gao J; Chakravarty D; Devlin SM; Hellmann MD; Barron DA; Schram AM; Hameed M; Dogan S; Ross DS; Hechtman JF; DeLair DF; Yao J; Mandelker DL; Cheng DT; Chandramohan R; Mohanty AS; Ptashkin RN; Jayakumaran G; Prasad M; Syed MH; Rema AB; Liu ZY; Nafa K; Borsu L; Sadowska J; Casanova J; Bacares R; Kiecka IJ; Razumova A; Son JB; Stewart L; Baldi T; Mullaney KA; Al-Ahmadie H; Vakiani E; Abeshouse AA; Penson AV; Jonsson P; Camacho N; Chang MT; Won HH; Gross BE; Kundra R; Heins ZJ; Chen HW; Phillips S; Zhang H; Wang J; Ochoa A; Wills J; Eubank M; Thomas SB; Gardos SM; Reales DN; Galle J; Durany R; Cambria R; Abida W; Cercek A; Feldman DR; Gounder MM; Hakimi AA; Harding JJ; Iyer G; Janjigian YY; Jordan EJ; Kelly CM; Lowery MA; Morris LGT; Omuro AM; Raj N; Razavi P; Shoushtari AN; Shukla N; Soumerai TE; Varghese AM; Yaeger R; Coleman J; Bochner B; Riely GJ; Saltz LB; Scher HI; Sabbatini PJ; Robson ME; Klimstra DS; Taylor BS; Baselga J; Schultz N; Hyman DM; Arcila ME; Solit DB; Ladanyi M; Berger MF
Nat Med; 2017 Jun; 23(6):703-713. PubMed ID: 28481359
[TBL] [Abstract][Full Text] [Related]
3. Genomic characterization of metastatic breast cancers.
Bertucci F; Ng CKY; Patsouris A; Droin N; Piscuoglio S; Carbuccia N; Soria JC; Dien AT; Adnani Y; Kamal M; Garnier S; Meurice G; Jimenez M; Dogan S; Verret B; Chaffanet M; Bachelot T; Campone M; Lefeuvre C; Bonnefoi H; Dalenc F; Jacquet A; De Filippo MR; Babbar N; Birnbaum D; Filleron T; Le Tourneau C; André F
Nature; 2019 May; 569(7757):560-564. PubMed ID: 31118521
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
5. Genomics to select treatment for patients with metastatic breast cancer.
Andre F; Filleron T; Kamal M; Mosele F; Arnedos M; Dalenc F; Sablin MP; Campone M; Bonnefoi H; Lefeuvre-Plesse C; Jacot W; Coussy F; Ferrero JM; Emile G; Mouret-Reynier MA; Thery JC; Isambert N; Mege A; Barthelemy P; You B; Hajjaji N; Lacroix L; Rouleau E; Tran-Dien A; Boyault S; Attignon V; Gestraud P; Servant N; Le Tourneau C; Cherif LL; Soubeyran I; Montemurro F; Morel A; Lusque A; Jimenez M; Jacquet A; Gonçalves A; Bachelot T; Bieche I
Nature; 2022 Oct; 610(7931):343-348. PubMed ID: 36071165
[TBL] [Abstract][Full Text] [Related]
6. The patterns and dynamics of genomic instability in metastatic pancreatic cancer.
Campbell PJ; Yachida S; Mudie LJ; Stephens PJ; Pleasance ED; Stebbings LA; Morsberger LA; Latimer C; McLaren S; Lin ML; McBride DJ; Varela I; Nik-Zainal SA; Leroy C; Jia M; Menzies A; Butler AP; Teague JW; Griffin CA; Burton J; Swerdlow H; Quail MA; Stratton MR; Iacobuzio-Donahue C; Futreal PA
Nature; 2010 Oct; 467(7319):1109-13. PubMed ID: 20981101
[TBL] [Abstract][Full Text] [Related]
7. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
8. Clinical reliability of genomic data obtained from spinal metastatic tumor samples.
Barzilai O; Martin A; Reiner AS; Laufer I; Schmitt A; Bilsky MH
Neuro Oncol; 2022 Jul; 24(7):1090-1100. PubMed ID: 34999837
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
[TBL] [Abstract][Full Text] [Related]
10. Genomics alterations of metastatic and primary tissues across 15 cancer types.
Liu G; Zhan X; Dong C; Liu L
Sci Rep; 2017 Oct; 7(1):13262. PubMed ID: 29038591
[TBL] [Abstract][Full Text] [Related]
11. Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types.
Topham JT; Titmuss E; Pleasance ED; Williamson LM; Karasinska JM; Culibrk L; Lee MKC; Mendis S; Denroche RE; Jang GH; Kalloger SE; Wong HL; Moore RA; Mungall AJ; O'Kane GM; Knox JJ; Gallinger S; Loree JM; Mager DL; Laskin J; Marra MA; Jones SJM; Schaeffer DF; Renouf DJ
Mol Cancer Ther; 2020 Sep; 19(9):1889-1897. PubMed ID: 32518206
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
13. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
15. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer whole-genome comparison of primary and metastatic solid tumours.
Martínez-Jiménez F; Movasati A; Brunner SR; Nguyen L; Priestley P; Cuppen E; Van Hoeck A
Nature; 2023 Jun; 618(7964):333-341. PubMed ID: 37165194
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.
Biswas R; Gao S; Cultraro CM; Maity TK; Venugopalan A; Abdullaev Z; Shaytan AK; Carter CA; Thomas A; Rajan A; Song Y; Pitts S; Chen K; Bass S; Boland J; Hanada KI; Chen J; Meltzer PS; Panchenko AR; Yang JC; Pack S; Giaccone G; Schrump DS; Khan J; Guha U
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001263. PubMed ID: 27900369
[TBL] [Abstract][Full Text] [Related]
18. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
Lee JY; Yoon JK; Kim B; Kim S; Kim MA; Lim H; Bang D; Song YS
BMC Cancer; 2015 Feb; 15():85. PubMed ID: 25881093
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of next-generation sequencing-based panel tests for malignant ovarian tumors.
Saotome K; Chiyoda T; Aimono E; Nakamura K; Tanishima S; Nohara S; Okada C; Hayashi H; Kuroda Y; Nomura H; Susumu N; Iwata T; Yamagami W; Kataoka F; Nishihara H; Aoki D
Cancer Med; 2020 Oct; 9(20):7407-7417. PubMed ID: 32813918
[TBL] [Abstract][Full Text] [Related]
20. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
